Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Pharm Res. 2010 Oct;27(10):2106-18. doi: 10.1007/s11095-010-0212-9. Epub 2010 Jul 24.
Evaluating the potentials of particulate delivery systems in topical drug delivery.
Polymethacrylate microparticles (MPs) incorporating verapamil hydrochloride (VRP) as a model hydrophilic drug with potential topical clinical uses, using Eudragit RS100 and Eudragit L100 were prepared for the formulation of a composite topical gel. The effect of initial drug loading, polymer composition, particularly the proportion of Eudragit L100 as an interacting polymer component and the HLB of the dispersing agent on MPs characteristics was investigated. A test MPs formulation was incorporated in gel and evaluated for drug release and human skin permeation.
MPs showed high % incorporation efficiency and % yield. Composition of the hybrid polymer matrix was a main determinant of MPs characteristics, particularly drug release. Factors known to influence drug release such as MPs size and high drug solubility were outweighed by strong VRP-Eudragit L100 interaction. The developed MPs gel showed controlled VRP release and reduced skin retention compared to a free drug gel.
Topical drug delivery and skin retention could be modulated using particulate delivery systems. From a practical standpoint, the VRP gel developed may offer advantage in a range of dermatological conditions, in response to the growing off-label topical use of VRP.
评估微粒给药系统在局部药物传递中的潜力。
采用 Eudragit RS100 和 Eudragit L100 作为模型亲水性药物盐酸维拉帕米(VRP)的聚合物微球(MPs),制备复合局部凝胶。考察了初始药物载药量、聚合物组成、特别是作为相互作用聚合物成分的 Eudragit L100 的比例和分散剂的 HLB 对 MPs 特性的影响。将一种测试 MPs 配方纳入凝胶中,并评估其药物释放和人体皮肤渗透情况。
MPs 表现出高的载药效率和产率。混合聚合物基质的组成是 MPs 特性的主要决定因素,特别是药物释放。影响药物释放的因素,如 MPs 的大小和高药物溶解度,被 VRP-Eudragit L100 之间的强相互作用所抵消。与游离药物凝胶相比,所开发的 MPs 凝胶显示出 VRp 的控制释放和减少皮肤滞留。
可以使用微粒给药系统调节局部药物传递和皮肤滞留。从实际的角度来看,所开发的 VRP 凝胶可能在一系列皮肤病条件下具有优势,以满足 VRP 越来越多的非标签局部应用的需求。